Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants - Concepedia

Concepedia

Publication | Open Access

Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants

DOI Full Paper Access

23

Citations

26

References

2024

Year

Gebremedhin Beedemariam Gebretekle, Man Wah Yeung, Raphael Ximenes, Alexandra Cernat, Alison E. Simmons, April Killikelly, Winnie Siu, Ellen Rafferty, Nicholas Brousseau, Matthew Tunis,

Abstract

Prophylactic interventions can substantially reduce RSV disease in infants, and more focused nirsevimab programs are the most cost-effective option at current product prices.

References

	Year	Citations

Page 1